title: Posterior reversible encephalopathy syndrome after intravitreal bevacizumab injection in patient with choroidal neovascular membrane secondary to age-related maculopathy.
abstract: The posterior reversible encephalopathy syndrome (PRES), a complex of cerebral disorders including headache, seizures, visual disturbances, is associated with a variety of conditions in which blood pressure rises acutely. Arterial hypertension can occur in systemic administration of bevacizumab. A few cases of systemic injection of bevazicumab-induced PRES have been reported. In this article, we first report on a patient who developed PRES following intravitreal bevazicumab.
authors.affiliation: Department of Ophthalmology, Istanbul Bilim University, Istanbul, Turkey. artunay@gmail.com
authors.forename: Ozgur
authors.initials: O
authors.lastname: Artunay
authors.forename: Erdal
authors.initials: E
authors.lastname: Yuzbasioglu
authors.forename: Rifat
authors.initials: R
authors.lastname: Rasier
authors.forename: Alper
authors.initials: A
authors.lastname: Sengul
authors.forename: Halil
authors.initials: H
authors.lastname: Bahcecioglu
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000150:complications; D008297:Male; D054038:Posterior Leukoencephalopathy Syndrome / Q000139:chemically induced*; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab